Xenetic Biosciences (XBIO)
Develops DNase-based adjuncts for cancer therapy and armored CAR-T treatment.
Something off on this page? Send us feedback.
Develops DNase-based cancer-treatment adjuncts, including systemic DNase I and a DNase I-armored CAR-T approach. Its asset-light program relies on third parties, while all revenue comes from royalties on a legacy PolyXen sublicense.
Develops systemic DNase I and DNase I-armored CAR-T programs intended to clear neutrophil extracellular traps that may hinder cancer treatment. XBIO-015 targets pancreatic carcinoma and other solid tumors, while XBIO-020 is designed to deliver DNase I in the tumor microenvironment alongside CAR-T tumor-killing activity.
Operates through external specialists: candidate manufacturing, preclinical research, translational work and exploratory studies span United States partners and Israeli medical centers. Its only revenue is royalty income from a Takeda sublicense of legacy PolyXen patents, not drug sales.
Maintains no internal research facility and depends on contract manufacturers, contract research organizations, academic institutions, consultants, licensed rights from CLS Therapeutics and investigator-led study partners.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.5M · Total debt $0 · Total assets $7.0M · Shareholders' equity $6.1M
- Revenue
- $660.6K
- Operating income
- −$971.7K
- Net income
- −$929.7K
No dividends on record.
| Insiders | 4.27% | 100.0K shares | |
|---|---|---|---|
| 1 holder · as of Apr 23, 2026 | |||
| Other | 95.73% | 2.24M shares | |
| remainder | |||
2.34M company shares as of Sep 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Renaissance Technologies LLCInstitution | 5.87% | 137,440 | filed May 14, 2026 |
James F. ParslowInsiderofficer: Interim CEO and CFO | 4.27% | 100,000 | filed Apr 23, 2026 |
Altium Growth Fund, LPInstitution | —9.80% of class, as filed | — | filed Jul 25, 2019 |
Empery Asset Management, LPInstitution | —9.99% of class, as filed | — | filed Mar 11, 2019 |
Heights Capital Management, Inc.Strategic | —8.90% of class, as filed | — | filed Aug 7, 2019 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Gilead Sciences
Approved CD19 CAR-T standard in large B-cell lymphoma.
- Bristol-Myers Squibb
Approved CD19 CAR-T benchmark with broad large B-cell lymphoma use.
- Novartis (ADR)
Approved CD19 CAR-T benchmark for large B-cell lymphoma.
- Allogene Therapeutics
Clinical allogeneic CD19 CAR-T challenger in large B-cell lymphoma.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Xenetic Biosciences | $2.60 | +1.17% | $6.9M | — | — | 2.1 | +12.0% |
| Gilead Sciences | $152.66 | −0.01% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Bristol-Myers Squibb | $62.25 | +0.01% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| Novartis (ADR) | $141.28 | +0.01% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Allogene Therapeutics | $1.73 | +1.47% | $583.3M | — | — | 125.7 | — |
| Median | 17.5 | 15.0 | 5.5 | +5.7% |